Q-omics provides the consensus-scored IPO4 profile across patient tissues and cancer cell-line models. IPO4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, IPO4 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, IPO4 protein abundance shows 21,332 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, COAD, and LUAD as cancer lineages where IPO4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IPO4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IPO4 survival associations across molecular data types. IPO4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IPO4 RNA expression–survival associations across cancer types. High IPO4 expression shows unfavorable associations in ACC, LIHC, KICH, LUAD, SKCM and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for IPO4 RNA expression.
This table summarizes IPO4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for IPO4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IPO4 shows higher tumor expression in COAD, LUAD, LIHC, KIRP, BLCA and LUSC. The COAD box plot shows higher IPO4 RNA expression in tumor versus normal tissue (log2 FC = +1.147, t-test p < 0.001).
This table shows molecular features associated with IPO4 in patient tissues and cancer cell lines. In patient samples, IPO4 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, IPO4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
